A PHASE II PROSPECTIVE RANDOMIZED DOUBLE-MASKED CONTROLLED STUDY ASSESSING THE SAFETY & EFFICACY OF RHPRG4 (450 µG/ML RECOMBINANT HUMAN PROTEOGLYCAN 4) COMPARED TO VEHICLE FOR THE TREATMENT OF SJÖGREN'S RELATED DRY EYE DISEASE

NCT07118241 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

80

Enrollment

INDUSTRY

Sponsor class

Conditions

Sjögren's Syndrome

Interventions

DRUG: Recombinant Human Proteoglycan 4
DRUG: Vehicle Control

Sponsor

Lubris Bio Pty Ltd